TerSera Therapeutics
TerSera Therapeutics is a privately held, GTCR-backed specialty biopharmaceutical company that acquires and commercializes differentiated FDA-approved therapeutics in oncology and rare disease, marketing ZOLADEX, MARGENZA, XERMELO, and VARUBI to specialty prescribers in the US and Canada.
- Company typePrivate
- Founded2016
- HeadquartersLake Forest, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What TerSera Therapeutics does
TerSera Therapeutics is a privately held, GTCR-backed specialty biopharmaceutical company founded in 2016 and headquartered in Deerfield, Illinois, with an additional regional office in Markham, Ontario (TerSera Canada Inc.) and a Florida office in Naples. The company acquires and commercializes differentiated, FDA-approved therapeutics in oncology and rare disease, operating under a "one-and-only" thesis of in-licensing or acquiring unique products with untapped clinical potential. Its core marketed portfolio consists of four assets: ZOLADEX (goserelin acetate implant), an LHRH agonist for prostate cancer, breast cancer, and certain gynecological indications; MARGENZA (margetuximab-cmkb), an Fc-engineered anti-HER2 monoclonal antibody for metastatic HER2-positive breast cancer; XERMELO (telotristat ethyl), a tryptophan hydroxylase inhibitor for carcinoid syndrome diarrhea; and VARUBI (rolapitant), an NK-1 receptor antagonist for chemotherapy-induced nausea and vomiting. The company divested its Infusion Specialty Therapies Business Unit (PRIALT and QUZYTTIR) to ESTEVE in March 2026, exiting non-oncology intrathecal and injectable assets to focus on the oncology and rare-disease core.
TerSera Therapeutics firmographics
Firmographics- Name
- TerSera Therapeutics
- Legal name
- TerSera Therapeutics LLC
- Website
- https://tersera.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- TerSera Therapeutics is a privately held, GTCR-backed specialty biopharmaceutical company that acquires and commercializes differentiated FDA-approved therapeutics in oncology and rare disease, marketing ZOLADEX, MARGENZA, XERMELO, and VARUBI to specialty prescribers in the US and Canada.
- Ownership category
- akta.pro rank
TerSera Therapeutics industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
Keywords
Where TerSera Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Lake Forest
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
TerSera Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Marketing or Sales, Technology or R&D, Operations
Revenue model
- Specialty Pharmaceutical Sales: TerSera generates revenue through the sale of FDA-approved specialty pharmaceutical products in oncology and non-opioid pain management. Revenue is derived from product sales to healthcare providers and through specialty pharmacy distribution channels.
- Licensing and Royalty Income: The company obtains commercial rights to products through licensing agreements and generates revenue from product sales. As of 2024-2026, the company expanded its portfolio through acquisitions including MARGENZA from MacroGenics for $40M plus potential milestones, and previously acquired rights to ZOLADEX, VARUBI, XERMELO, and PRIALT through various licensing and asset purchase agreements.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
TerSera Therapeutics product offering
Product offeringCore offering
TerSera Therapeutics acquires, develops, and commercializes a portfolio of FDA-approved specialty pharmaceuticals focused on oncology and rare diseases. Core marketed products include ZOLADEX (goserelin implant) for hormone-sensitive cancers, MARGENZA (margetuximab-cmkb) for metastatic HER2-positive breast cancer, XERMELO (telotristat ethyl) for carcinoid syndrome diarrhea, and VARUBI (rolapitant) for chemotherapy-induced nausea. The company supplements its therapeutic portfolio with TerSera SupportSource and TerSera NurseSupport patient access programs.
Product overview
TerSera Therapeutics is a biopharmaceutical company that operates a differentiated portfolio of FDA-approved specialty medicines organized around oncology and non-opioid pain management. The company's core product portfolio consists of four marketed therapeutics: ZOLADEX (goserelin acetate implant), a GnRH agonist for hormone-sensitive cancers and gynecological disorders; MARGENZA (margetuximab-cmkb), an Fc-engineered anti-HER2 monoclonal antibody for HER2-positive metastatic breast cancer; XERMELO (telotristat ethyl), a tryptophan hydroxylase inhibitor for carcinoid syndrome diarrhea; and VARUBI (rolapitant), an NK-1 receptor antagonist for chemotherapy-induced nausea and vomiting. TerSera commercializes these products through its U.S. and Canadian commercial infrastructure and supports patient access through TerSera SupportSource (reimbursement, copay, and patient assistance programs) and TerSera NurseSupport (clinical nurse education services).
Differentiator
Problem solved
Functional benefit
Products and services
- ZOLADEX (goserelin implant) Injectable luteinizing hormone-releasing hormone agonist (LHRHa) implant used to treat prostate cancer, breast cancer, and certain benign gynecological disorders. Available as a 3.6 mg implant dosed every 28 days or 10.8 mg implant dosed every 12 weeks. Used by oncologists, urologists, and women's health specialists.
- MARGENZA (margetuximab-cmkb) Fc-engineered monoclonal antibody targeting the HER2/neu receptor, approved in combination with chemotherapy for metastatic HER2-positive breast cancer in patients who have received two or more prior anti-HER2 regimens. Prescribed by oncologists.
- XERMELO (telotristat ethyl) Tryptophan hydroxylase inhibitor tablet indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy. Prescribed by oncologists and endocrinologists managing carcinoid syndrome.
- VARUBI (rolapitant) NK-1 receptor antagonist indicated for the prevention of delayed nausea and vomiting associated with chemotherapy. Prescribed by oncologists in combination with other antiemetic regimens.
- TerSera SupportSource Comprehensive patient support services providing insurance benefit investigations, prior authorization information, appeals support, reimbursement questions, copay support for eligible patients, and Patient Assistance Program for those with financial need. Available to patients prescribed TerSera therapeutics.
- TerSera NurseSupport Dedicated nursing support offering one-on-one help for healthcare providers and patients, including education on treatment initiation, tracking, and condition-related topics for TerSera therapies.
Quantifiable outcome
- ZOLADEX 10.8mg demonstrated non-inferiority to 3.6mg at 12-month rwEFS (79.2% vs 76.6%, treatment difference 2.7%)
- +2 more outcomes
Companies that use TerSera Therapeutics
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
TerSera Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TerSera Therapeutics partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- ESTEVEcoreESTEVE acquired TerSera's Infusion Specialty Therapies Business Unit including PRIALT (ziconotide) and QUZYTTIR (cetirizine) for an undisclosed amount. The transaction closed in March 2026. ESTEVE had previously partnered with TerSera for PRIALT distribution in Europe.
- Pentec HealthminorTerSera partnered with Pentec Health for a retrospective, non-interventional study analyzing real-world ziconotide prescribing patterns from over 1,000 patients between 2017-2024 using Pentec's dispensing and claims records.
- MacroGenicscoreTerSera acquired global rights to MARGENZA (margetuximab-cmkb) from MacroGenics for $40 million at closing plus up to $35 million in sales milestones. MARGENZA is an Fc-engineered monoclonal antibody for metastatic HER2-positive breast cancer. The transaction closed in Q4 2024.
- Lexicon PharmaceuticalscoreLexicon Pharmaceuticals entered into an agreement with TerSera for XERMELO (telotristat ethyl) for the treatment of carcinoid syndrome diarrhea. TerSera acquired commercial rights to this tryptophan hydroxylase inhibitor.
- Jazz PharmaceuticalscoreJazz Pharmaceuticals entered into an agreement with TerSera for PRIALT (ziconotide). This partnership was later transferred to ESTEVE as part of the Infusion Specialty Therapies divestiture in 2026.
- TESAROcoreTESARO entered into an asset purchase agreement with TerSera for VARUBI (rolapitant) in the U.S. and Canada. TerSera acquired commercial rights to this NK-1 receptor antagonist for chemotherapy-induced nausea and vomiting.
- AstraZenecacoreAstraZeneca entered into an agreement with TerSera for commercial rights to ZOLADEX (goserelin acetate implant) in the US and Canada, with transaction closing in Q1 2017. TerSera serves as the commercial partner while AstraZeneca retains manufacturing and supply responsibilities.
- SERBminorSERB is listed as a global partnership alongside AstraZeneca on TerSera's partnerships page, indicating a collaborative relationship in the pharmaceutical space.
Scale indicators3 records
Recent moves8 records
Expansion highlights5 records
TerSera Therapeutics competitors and assessment
Company assessmentDirect peers
- Eagle Pharmaceuticals: Specialty pharma developing and commercializing differentiated injectables and oncology supportive-care products. Comparable hospital/specialty channel focus and product-relaunch strategy to TerSera.
- Assertio Therapeutics: Specialty pharma focused on pain, neurology, and specialty markets with a similar 'acquire-and-relaunch' commercial model. TerSera CCO Mark Booth previously served as CCO at Assertio, indicating close operational overlap in commercial approach and target prescriber base.
- HLS Therapeutics: Canadian-headquartered specialty pharma commercializing therapeutics in oncology, urology, and rare diseases. Mirrors TerSera's US/Canada go-to-market, prescriber focus, and specialty pharmaceutical asset acquisition strategy.
- US WorldMeds: Specialty pharma focused on pain, rare disease, and specialty therapeutics with a similar in-licensing and niche-marketing playbook. Overlaps with TerSera's prior non-opioid pain franchise and rare-disease expansion strategy.
- Collegium Pharmaceutical: Specialty pharma focused on responsible pain management with a portfolio of differentiated pain therapeutics. Overlaps with TerSera's non-opioid pain positioning and specialty salesforce model.
- ANI Pharmaceuticals: Specialty pharma combining branded prescription products with specialty generics, focused on rare disease, oncology supportive care, and women's health. Comparable business model and therapeutic-area breadth.
Broad incumbents
- Endo International: Specialty pharma with focus on branded specialty, sterile injectables, and pain therapeutics. Comparable in therapeutic focus areas (oncology supportive care, pain, rare disease) and in commercial model of acquiring specialty assets from larger pharma.
- Mallinckrodt Pharmaceuticals: Diversified specialty pharma with franchises in specialty branded, generics, and rare disease, including pain. Larger incumbent operating overlapping therapeutic categories (oncology supportive care, rare endocrine) with broader portfolio scale than TerSera.
Emerging players
- Tolmar Pharmaceuticals: Specialty pharma with urology and oncology focus, including hormone-sensitive cancer therapies. Direct competitor to TerSera's ZOLADEX in certain prostate cancer and gynecology segments.
- Puma Biotechnology: Oncology company commercializing NERLYNX for HER2+ breast cancer. Directly competes with MARGENZA in HER2+ metastatic breast cancer and represents the most relevant therapeutic-area peer to TerSera's newest acquisition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
TerSera Therapeutics social profiles
Digital presenceTerSera Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
TerSera Therapeutics leadership team
Management profileNumber of profiles
Profiles12 records
TerSera Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
TerSera Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TerSera Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TerSera Therapeutics
What does TerSera Therapeutics do?
TerSera Therapeutics acquires, develops, and commercializes a portfolio of FDA-approved specialty pharmaceuticals focused on oncology and rare diseases. Core marketed products include ZOLADEX (goserelin implant) for hormone-sensitive cancers, MARGENZA (margetuximab-cmkb) for metastatic HER2-positive breast cancer, XERMELO (telotristat ethyl) for carcinoid syndrome diarrhea, and VARUBI (rolapitant) for chemotherapy-induced nausea. The company supplements its therapeutic portfolio with TerSera SupportSource and TerSera NurseSupport patient access programs.
Is TerSera Therapeutics a public or private company?
TerSera Therapeutics is a private company. It is classified as private equity controlled and is currently operating.
When was TerSera Therapeutics founded?
TerSera Therapeutics was founded in 2016. It employs 101 to 250 people.
Where is TerSera Therapeutics based?
TerSera Therapeutics is headquartered in Lake Forest, United States, in the North America region.
How does TerSera Therapeutics make money?
Two revenue lines are on record. Specialty Pharmaceutical Sales are the primary driver. The others are licensing and Royalty Income.
Who are TerSera Therapeutics's main competitors?
Direct peers on record are Eagle Pharmaceuticals, Assertio Therapeutics, HLS Therapeutics, US WorldMeds, Collegium Pharmaceutical and ANI Pharmaceuticals. Broad incumbents are Endo International and Mallinckrodt Pharmaceuticals. Emerging players are Tolmar Pharmaceuticals and Puma Biotechnology.
Does TerSera Therapeutics have an API?
No public API is recorded for TerSera Therapeutics.
What industry is TerSera Therapeutics in?
TerSera Therapeutics's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 3254 and its SIC code is 2834.